1 |
Parsonnet, J., R. A. Harris, H. M. Hack and D. K. Owens. 1996. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer; A mandate for clinical trials. Lancet 348, 150-154
DOI
ScienceOn
|
2 |
Ruggiero, P., P. Samuele, R. Rino and D. G. Giuseppe. 2003. The quest for a vaccine against Helicobacter pylori: How to move from mouse to man? Micro. Infec. 5, 749-756
DOI
ScienceOn
|
3 |
Rupnow, M. F., D. K. Owens, R. Shachter and J. Parsonnet. 1999. Helicobacter pylori vaccine development and use: A cost-effectiveness analysis using the institute of Medicine methodology. Helicobacter 4, 272-280
DOI
ScienceOn
|
4 |
Rupnow, M. F., R. D. Shachter, D. K. Owens and J. Parsonnet. 2001. Quantifying the population impact of a prophylactic Helicobacter pylori vaccine. Vaccine 20, 879-885
DOI
ScienceOn
|
5 |
Satoh, K., K. Kimura and Y. Taniguchi. 1996. Distribution of inflammation and atrophy in the stomach of Helicobacter pylori-positive and -negative patients with chronic gastritis. Am. J. Gastroenterol 91, 963-969
|
6 |
Simon, P. M., P. L. Goode, A. Mobasseri and D. Zopf. 1997. Inhibition of Helicobacter pylori binding to gastrointestinal infect. Immun. 65, 750-757
|
7 |
Warren, J. R. and B. Marshall. 1983. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 4, 1273-1275
|
8 |
IARC working group on the evaluation of carcinogenic risks to humans. 1994. Helicobacter pylori. in: Schistosomes, liver flukes, and Helicobacter pylori: views and expert opinions of IARC working group on the evaluation of carcirogenic risks to humans. Lyon: IARC Monogr Eval Carcinog Risks Hum. 61-241
|
9 |
Jo, E. H., S. D. Cho, N. S. Ahn, J. W.Jung, S. R. Yang, J. S. Park, K. S. Park, I. S. Hong, M. S. Seo, N. B. Tiep, Y. S. Lee and K. S. Kang. 2003. Antigenicity study of nonspecific immunostimulator . Kor. J. Vet. Res. 43, 255-261
|
10 |
Marshall, B. J. and J. R. Warren. 1984. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 323, 1311-1315
DOI
ScienceOn
|
11 |
Megraud, F. 1998. Antibiotic resistance in Helicobacter pylori infection. Br. Med. Bull. 24, 207-216
|
12 |
Michetti, P., I. Corthésy-Theulaz, C. Davin, R. Haas, A. C. Vaney, M. Heitz, J. Bille, J. P. Kraehenbuhl, E. Saraga and A. L. Blum. 1994. Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology 107, 1002-1011
DOI
|
13 |
Blanchard, T. G., J. C. Eisenberg and Y. Matsumoto. 2004. Clearance of Helicobacter pylori infection through immunization: the site of T cell activation contributes to vaccine efficacy. Vaccine 22, 888-897
DOI
ScienceOn
|
14 |
Garhart, C. A., R. W. Redline, J. G. Nedrud and S. J. Czinn. 2002. Clearance of Helicobacter pylori infection and resolution of postimmunization gastritis in a kinetic study of prophylactically immunized mice. Infect. Immun. 3529-3538
|
15 |
Graham, D. Y., H. M. Malaty, D. G. Evans, D. J. Jr Evans, P. D. Klein and E. Adam. 1991. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 100, 1495-1501
DOI
|
16 |
Hunt, R. H. 1996. Eradication of Helicobacter pylori infection. Am. J. Med. 100 (5A) 42S-50S
DOI
ScienceOn
|
17 |
Hayashi, K., T. Ishikawa, T. Yamashita, T. Tajima and K. Nakayama. 2003. Biphasic response of cutaneous blood flow induced by passive cutaneous anaphylaxis in rats. Eur. J. Pharmacol. 482, 305-311
DOI
ScienceOn
|
18 |
Hifumi, E., Y. Yamada and T. Uda. 2006. A catalytic antibody heavy chain HpU-2 degrading its epitope peptide and H. pylori Urease. Immunol. Lett. 103, 68-74
DOI
ScienceOn
|
19 |
Hu, L. T. and H. L. Mobley. 1990. Purification and N-Terminal analysis of urease from Helicobacter pylori. Infect. Immun. 58, 992-998
|
20 |
Kim, B. J., B. H. Kang, T. Y. Kim, T. H. Kim and K. W. Kim. 1997. Production and characterization of IgY specific to Helicobacter pylori. Kor. J. Appl. Microbiol. Biotechnol. 25, 612-616
|
21 |
Mabe, K., M. Yamada, I. Oguni and T. Takahashi. 1999. In vitro and in vivo activities of tea catechins against Helicobacter pylori. Antimicrob Agents Chemother. 43, 1788-1791
|
22 |
Justine, S. G., E. C. Natalie and H. S. Dieter. 1980. Methods in immunology, a laboratory text for instruction and research. W. A. Benjamin, Inc, Canada
|
23 |
Lee, D. H. 2002. Current status and treatment of Helicobacter pyri infection in korea. Kor. J. Gastrol. 39, 153-160
|
24 |
Lesley, E., M. J. Smythies, K. B. Novak, J. Waites, L. Russell, D. M. Casey and D. S. Phillip. 2005. Poliovirus replicons encoding the B subunit of Helicobacter pylori urease protect mice against H. pylori infection. Vaccine 23, 901-909
DOI
ScienceOn
|
25 |
Ermak, T. H., P. J. Giannasca, R. Nichols, G. A. Myers, J. Nedrud, R. Weltzin, C. K. Lee, H. Kleanthous and T. P. Monath. 1998. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II- restricted responses. J. Exp. Med. 188, 2277-2288
DOI
ScienceOn
|
26 |
Birmingham, N., S. Payankaulam, S. Thanesvorakul, B. Stefura, K. HayGlass and V. Gangur. 2003. An ELISAbased method for measurement of food-specific IgE antibody in mouse serum: an alternative to the passive cutaneous anaphylaxis assay. J. Immunol. Methods 275, 89-98
DOI
ScienceOn
|